rs61753209
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000287.4(PEX6):βc.311delβ(p.Gly104ValfsTer22) variant causes a frameshift change. The variant allele was found at a frequency of 0.0000409 in 1,516,872 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000020 ( 0 hom., cov: 33)
Exomes π: 0.000043 ( 0 hom. )
Consequence
PEX6
NM_000287.4 frameshift
NM_000287.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.74
Genes affected
PEX6 (HGNC:8859): (peroxisomal biogenesis factor 6) This gene encodes a member of the AAA (ATPases associated with diverse cellular activities) family of ATPases. This member is a predominantly cytoplasmic protein, which plays a direct role in peroxisomal protein import and is required for PTS1 (peroxisomal targeting signal 1, a C-terminal tripeptide of the sequence ser-lys-leu) receptor activity. Mutations in this gene cause peroxisome biogenesis disorders of complementation group 4 and complementation group 6. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 6-42978839-AC-A is Pathogenic according to our data. Variant chr6-42978839-AC-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 499109.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PEX6 | NM_000287.4 | c.311del | p.Gly104ValfsTer22 | frameshift_variant | 1/17 | ENST00000304611.13 | NP_000278.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PEX6 | ENST00000304611.13 | c.311del | p.Gly104ValfsTer22 | frameshift_variant | 1/17 | 1 | NM_000287.4 | ENSP00000303511 | P1 | |
PEX6 | ENST00000244546.4 | c.311del | p.Gly104ValfsTer22 | frameshift_variant | 1/15 | 1 | ENSP00000244546 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 151930Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
3
AN:
151930
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000178 AC: 2AN: 112424Hom.: 0 AF XY: 0.0000160 AC XY: 1AN XY: 62496
GnomAD3 exomes
AF:
AC:
2
AN:
112424
Hom.:
AF XY:
AC XY:
1
AN XY:
62496
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000432 AC: 59AN: 1364942Hom.: 0 Cov.: 36 AF XY: 0.0000342 AC XY: 23AN XY: 673454
GnomAD4 exome
AF:
AC:
59
AN:
1364942
Hom.:
Cov.:
36
AF XY:
AC XY:
23
AN XY:
673454
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 151930Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74204
GnomAD4 genome
AF:
AC:
3
AN:
151930
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
74204
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Peroxisome biogenesis disorder Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 18, 2022 | Variant summary: PEX6 c.311delG (p.Gly104ValfsX22) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 1.8e-05 in 112824 control chromosomes (gnomAD and publication data). c.311delG has been reported in the literature in at least one compound heterozygous individual affected with Zellweger Syndrome (Ebberink_2010). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four ClinVar submitters (evaluation after 2014) cite the variant as pathogenic (n=3) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 13, 2024 | This sequence change creates a premature translational stop signal (p.Gly104Valfs*22) in the PEX6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PEX6 are known to be pathogenic (PMID: 10408779, 21031596, 31831025). This variant is present in population databases (rs61753209, gnomAD 0.005%). This premature translational stop signal has been observed in individual(s) with PEX6-related disorders (PMID: 19877282). ClinVar contains an entry for this variant (Variation ID: 499109). For these reasons, this variant has been classified as Pathogenic. - |
PEX6-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 11, 2024 | The PEX6 c.311delG variant is predicted to result in a frameshift and premature protein termination (p.Gly104Valfs*22). This variant has been reported in an individual with Zellweger syndrome (Table 2, Ebberink et al. 2010. PubMed ID: 19877282). This variant is reported in 0.0052% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in PEX6 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Peroxisome biogenesis disorder 4A (Zellweger);C3553937:Peroxisome biogenesis disorder 4B Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Sep 06, 2017 | - - |
Zellweger spectrum disorders Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Feb 01, 2021 | - - |
Heimler syndrome 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 01, 2024 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 19, 2016 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at